Microdosing is a global revolution
in mental health care
The truffles of Fresh Mushrooms BV are a legal product of high quality in the Netherlands. This legal status of the psychoactive truffle in the Netherlands has allowed Fresh Mushrooms BV to build up years of experience in the cultivation of high quality psychoactive truffles, also suitable for the therapeutic application of micro-dosing. Cultivated under sterile conditions, the truffles are very suitable for microdosing. The XP Microdosing truffles are packed per 6 times one gram in a strip for optimal freshness. The truffles have an EU food safety mark (EU1881/2006).
More and more people are experiencing the positive effects of legal food safe psilocybin truffles. More and more people want to micro-dose. The truffle is a natural product that has an ancient tradition on almost all continents. By micro-dosing, a general feeling of well-being can arise at small doses. Of being more in the flow, more connected with others and yourself. Microdosing has an immense effect worldwide.
Opportunity for Pharma-co's: Psilocybin Truffles
The psychedelic drugs market is expected to witness market growth during the forecast period from 2020 to 2027. Data Bridge Market Research analyzes that the market is growing at a CAGR of 16.3% during the forecast period from 2020 to 2027 and is expected to reach USD 6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for the treatment of depression and increasing prevalence of depression and mental disorders are the factors driving the market growth.
Fresh Mushrooms BV has been leading the world's largest production of natural organic psilocybin mushrooms and truffles for over 25 years. Production and cultivation methods have evolved to meet the needs of the world. Industrial-scale production serves dozens of online shops, serves hundreds of thousands of repeat customers, dropshipping companies, R&D drug companies, smartshops and more. From XP branded solutions to white label solutions, Fresh Mushrooms BV (Ltd.) can meet the needs of the medical, R&D and pharmaceutical industries. Both as a source for research and for the production of psilocybin truffles for micro-dosage packages or as a basic source of psilocybin.
A Lancet Commission report on mental health states that mental disorders are increasing in every country in the world and could cost the global economy $ 16 trillion by 2030. According to the Anxiety and Depression Association of America (ADAA) , general anxiety affects 6.8 million adults, social anxiety affects 15 million, PTSD affects 7.7 million in the US alone, and depressive disorder is part of the lives of 16.1 million adults.
A study by Columbia University Medical Center (CUMC) and the University of Pennsylvania found that most Americans with depression are not getting the treatment they need. Despite the ongoing development of antidepressants, 50 per cent of patients see no measurable improvement after treatment and may experience unpleasant or even dangerous side effects. These drugs are prescribed to patients for years and can be addictive and psychologically damaging.
The US Food & Drug Administration is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance found in magic mushrooms, for the treatment of major depressive disorder (MDD). The FDA has designated psilocybin therapy - currently being tested in clinical trials - as a 'breakthrough therapy', an action designed to speed up the usually slow process of drug development and review.
One reason may be the need to consume psychedelics in a therapeutic setting. These food supplements must be used in a controlled setting and environment to be effective. This requires professional help and facilities to be trained and ready for effective therapy, which opens the door to private companies and retreats (truffle.report).
Psilocybin, at a single dose, could have a profound effect on the brain and long-lasting effects after wiping out depressive symptoms, the statement said. (Source: livescience.com).
With a bold prediction, we can see psilocybin truffle slowly micro-dosing over time, replacing antidepressants, ritalin, adderall, benzos and who knows what else... Currently, there are many promising scientific studies being conducted on depression, end of life cancer patients, anxiety , eating disorders, obsessive compulsive disorder, autism and much more. Investors or biotech or pharmaceutical companies that believe in the future of psychedelics are invited to contact us.